Portfolio company Crossbridge Bio to be acquired by Eli Lilly in a deal worth up to $300M.
CrossBridge Bio is an innovative oncology company focused on developing advanced antibody-drug conjugates (ADCs) for cancer treatment
CrossBridge Bio is an innovative oncology company focused on developing advanced antibody-drug conjugates (ADCs) for cancer treatment. The company is dedicated to redefining cancer therapies through cutting-edge platform technologies, dual-payload ADCs, and strategic collaborations.